Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity

Immunological Reviews

Volumn 171, Issue , 1999, Pages 27-44

  Ramsay, Alistair J ^a   Kent, Stephen J ^b   Strugnell, Richard A ^c   Suhrbier, Andreas ^d   Thomson, Scott A ^a   Ramshaw, Ian A ^a,d  

^a Biology and Environment   (Australia)

^b Macfarlane Burnet Ctr Med Research   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; CYTOKINE; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; RECOMBINANT VACCINE; VIRUS VECTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; AUTOIMMUNE DISEASE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOWLPOX VIRUS; GENE EXPRESSION; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOMODULATION; INTRANASAL DRUG ADMINISTRATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODY FORMATION; AUTOIMMUNE DISEASES; CYTOKINES; FOWLPOX VIRUS; GENETIC VECTORS; HUMANS; HYPERSENSITIVITY; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION, SECONDARY; PEPTIDES; VACCINATION; VACCINES, DNA;

EID: 2942573752     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01341.x     Document Type: Review

References (117)

1. 1. Mosmann TR, Coffman RL. Heterogenecity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-147.
2. 2. Yssel H, Schneider P, Spits H. Production of IL-4 by human T cells and regulation of differentiation of T cell subsets by IL-4. Res Immunol 1993;144;610-661.
3. 3. Ramsay AJ, Ruby J, Ramshaw IA. A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 1993;14:155-157.
4. 4. Zinkernagel RM. Immunology taught by viruses. Science 1996;271:173-178.
5. 5. Doherty PC. Cell mediated immunity in virus infections. Biosci Rep 1997;17:367-387.
6. 6. Calarota S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-1325.
7. 7. Finn R. DNA vaccines generate excitement as human trials begin. The Scientist 1998;12:9.
8. 8. Wang R, et al. Induction of antigen-specific cytotoxic lymphocytes in humans by a malaria DNA vaccine. Science 1998;282:476-480.
9. 9. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA 1993;90:11478-11482.
10. 10. Pardoll DM, Beckerleg AM. Exposing the immunology of naked DNA vaccines. Immunity 1995;3:165-169.
11. 11. Ramsay A, Leong K, Ramshaw I. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors. Immunol Cell Biol 1997;75:382-388.
12. 12. Somogyi P, Frazier J, Skinner MA. Fowlpox virus host range restriction: gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells. Virology 1993;197:439-444.
13. 13. Leong KH, Ramsay AJ, Morin MJ, Robinson HL, Boyle DB, Ramshaw IA. In: Brown F, Chanock H, Norrby E, eds. Generation of enhanced immune responses by consecutive immunisation with DNA and recombinant fowlpox viruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1995, p. 327-331.
14. 14. Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72:10180-10188.
15. 15. Ramshaw I, Ruby J, Ramsay A, Ada G, Karupiah G. Expression of cytokines by recombinant vaccinia viruses: a model for studying cytokines in virus infections in vivo, Immunol Rev 1992;127:157-182.
16. 16. Leong KH, Ramsay AJ, Boyle DB, Ramshaw IA. Selective induction of immune responses by cytokines coexpressed in recombinant fowlpox virus. J Virol 1994;68:8125-8130.
17. 17. Ramsay AJ, et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994;264:561-563.
18. 18. Ramshaw IA, Ramsay AJ, Karupiah G, Rolph M, Mahalingam S, Ruby J. Cytokines and immunity to viral infections. Immunol Rev 1997;159:119-135.
19. 19. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185:293-303.
20. 20. Miller CJ, McGhee JR, Gardner MB. Mucosal immunity, HIV transmission and AIDS. Lab Invest 1992;68:129.
21. 21. Ramsay AJ. Genetic approaches to the study of cytokine regulation of mucosal immunity. Immunol Cell Biol 1995;73:484-488.
22. 22. Mazzoli S, et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nat Med 1997;3:1250-1257.
23. 23. Ulmer JB, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-1749.
24. 24. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997;158:834-841.
25. 25. Staats HF, Montgomery SP, Palter TJ. Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses. AIDS Res Hum Retroviruses 1997;13:945-952.
26. 26. Klavinskis L, Barnfield C, Gao L, Parker S. Intranasal immunization with plasmid DNA-lipid complexes elicits mucosal immunity in the female genital and rectal tracts. J Immunol 1999;162:254-262.
27. 27. Rowland-Jones SL, et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
28. 28. Rowland-Jones S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995;1:59-64.
29. 29. Clerici M, et al. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 1994;8:1391-1395.
30. 30. Clerici M, et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. JAMA 1994;271:42-46.
31. 31. Borrow P, et al. Antiviral pressure exerted by HIV-1-specific CTLs during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
32. 32. Goulder PJ, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997;185:1423-1433.
33. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
34. 34. Koup RA, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
35. 35. Kent SJ, Woodward A, Zhao A. Human immunodeficiency virus type 1 (HIV-1)-specific T cell responses correlate with control of acute HIV-1 infection in macaques. J Infect Dis 1997;176:1188-1197.
36. + T cell responses associated with control of viremia. Science 1997;278;1447-1450.
37. + cytotoxic T lymphocytes. Science 1991;252:440-443.
38. 38. Daniel MD, et al. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses 1994;10:839-851.
39. 39. Stallard G, et al. Limits of protective immunity generated by SIVmne gp160 vaccines against cell-free homologous virus challenge. AIDS Res Hum Retroviruses 1994;10: S137.
40. + nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995;1:1167-1173.
41. + T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J Virol 1996;70:4941-4947.
42. 42. McElrath MJ, et al. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen. Proc Natl Acad Sci USA 1996;93:3972-3977.
43. 43. Cooney EL, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-572.
44. 44. Hu SL, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
45. 45. Hirsch VM, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV) infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
46. 46. Andersson S, et al. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis 1996;174:977-985.
47. 47. Egan MA, et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995;171:1623-1627.
48. 48. Fleury B, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996;174:734-738.
49. 49. Corey L, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. J Infect Dis 1998;177:301-309.
50. 50. Clements-Mann ML, et al. Immune responses to HIV-1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998;177:1230-1246.
51. 51. Boyer JD, et al. Protection of chimpanzees from high dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997;3:526-532.
52. 52. Lu S, et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978-3991.
53. 53. Letvin NL, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997;94:9378-9383.
54. 54. Fuller DH, et al. Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997;75:389-396.
55. 55. Ramshaw I, Andrew M, Phillips S, Boyle D, Coupar B. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987;329:545-546.
56. 56. Benson J, et al. Recombinant vaccine-induced protection against the highly pathogenic STVmac251: dependence on route of challenge exposure. J Virol 1998;72:4170-4182.
57. 57. Kim JJ, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997;158:816-826.
58. 58. Excler J-L, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997;11: S127-S137.
59. 59. Alexander J, Ruppert J, Snoke K, Sette A. TCR antagonism and T cell tolerance can be independently induced in a DR-restricted, hemagglutinin-specific T cell clone. Int Immunol 1994;6:363-367.
60. 60. Busch DH, Pamer EG. T cell affinity maturation by selective expansion during infection. J Exp Med 1999;189:701-710.
61. 61. Parish CR. The relationship between humoral and cell-mediated immunity. Transplant Rev 1972;13:35-66.
62. 62. Sher A, Coffman RL. Regulation of immunity to parasites by T cells and T cell-derived cytokines. Annu Rev Immunol 1992;10:385-409.
63. 63. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Cancer Res 1996;69:213-245.
64. 64. Rowland-Jones S, Tan R, McMichael A. Role of cellular immunity in protection against HIV infection. Adv Immunol 1997;65:277-346.
65. 65. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
66. 66. Uchijima M, Yoshida A, Nagata T, Koide Y. Optimization of codon usage of plasmid DNA vaccine is required for the effective MHC class I-restricted T cell responses against an intracellular bacterium. J Immunol 1998;161:5594-5599.
67. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397-402.
68. 68. Dick TP, et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 1996;86:253-262.
69. 69. Lopez D, Del Val M. Selective involvement of proteasomes and cysteine proteases in MHC class I antigen presentation. J Immunol 1997;159:5769-5772.
70. 70. Elliott T, Willis A, Cerundolo V, Townsend A. Processing of major histocompatibility class I-restricted antigens in the endoplasmic reticulum. J Exp Med 1995;181:1481-1491.
71. + T cell recognition of an endogenously processed epitope is regulated primarily by residues within the epitope. J Exp Med 1992;176:1335-1341.
72. 72. Niedermann G, et al. The proteolytic fragments generated by vertebrate proteasomes: structural relationships to major histocompatibility complex class I binding peptides. Proc Natl Acad Sci USA 1996;93:8572-8577.
73. 73. Yewdell JW, Bennink JR. Immunodominance in MHC class I-restricted T lymphocyte responses. Annu Rev Immunol (In press).
74. 74. Thomson SA, et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 1996;157:822-826.
75. + cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci USA 1995;92:5845-5849.
76. 76. Brasseur F, et al. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer 1995;63:375-380.
77. 77. Lehmann F, et al. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol 1995;25:340-347.
78. 78. Thomson SA, et al. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol 1998;160:1717-1723.
79. 79. Hanke T, et al. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
80. 80. Hislop AD, et al. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nat Med 1998;4:1193-1196.
81. + epitopes. J Virol 1999;73:5320-5325.
82. 82. An LL, Whitton JL. A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen. J Virol 1997;71:2292-2302.
83. + cytotoxic T lymphocytes: a novel approach to vaccine design. J Virol 1998;72:2246-2252.
84. 84. Ishioka GY, et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol 1999;162:3915-3925.
85. 85. Mulligan RC. The basic science of gene therapy. Science 1993;260:926-932.
86. 86. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
87. 87. Hogan SP, Foster PS, Tan X, Ramsay AJ. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity. Eur J Immunol 1998;28:413-423.
88. 88. Gavett SH, O'Hearn DJ, Li X, Huang SK, Finkelman FD, Wills KM. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. J Exp Med 1995;182:1527-1536.
89. 89. Li X-M, Chopra RK, Chou T-Y, Schofield BH, Wills-Karp M, Huang S-K. Mucosal IFN-γgene transfer inhibits pulmonary allergic responses in mice. J Immunol 1996;157:3216-3219.
90. 90. Powrie F, Coffman RL. Cytokine regulation of T cell function: potential for therapeutic intervention. Immunol Today 1993;14:270-274.
91. 91. O'Garra A, Murphy K. T-cell subsets in autoimmunity. Curr Opin Immunol 1993;5:880-886.
92. 92. Ando DG, Clayton J, Kong D, Urban JL, Sercarz EE. Encephalitogenic T cells in the B 10.Pl model of experimental allergic encephalomyelitis. Cell Immunol 1989;124:132-43.
93. 93. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-621.
94. 94. Ramshaw IA, Fordham SA, Bernard CCA, Maguire D, Cowden WB, Willenborg DO. DNA vaccines for the treatment of autoimmune disease. Immunol Cell Biol 1997;75:409-412.
95. 95. Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997;158:2278-2284.
96. 96. Fuller DH, Corb MM, Barnett S, Steimer K, Haynes JR. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997;15:924-926.
97. 97. Wang B, et al. Gene inoculation generates immune responses against immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:4146-4160.
98. 98. Saul A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine (In press).
99. 99. Boyle JS, Brady JL, Lew AM. Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. Nature 1998;392:408-411.
100. 100. Rothel JS, et al. Nucleic acid vaccination of sheep: use in combination with a conventional adjuvanted vaccine against Taenia ovis. Immunol Cell Biol 1997;75:41-46.
101. 101. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
102. 101. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat Biotech 1998;16:562-565.
103. 103. Strugnell RA, et al. DNA vaccines for bacterial infections. Immunol Cell Biol 1997;75:364-369.
104. 104. Yewdell JW, Frank E, Gerhard W. Expression of influenza A virus internal antigens on the surface of infected P815 cells. J Immunol 1981;126:1814-1819.
105. 105. Prokudina-Kantorovich EN, Semenova NP. Intracellular oligomerization of influenza virus nucleoprotein. Virology 1996;223:51-56.
106. 106. Tew JG, Wu J, Qin D, Helm S, Burton GF, Szakal AK. Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol Rev 1997;156:39-52.
107. 107. Ruigrok RW, Baudin F. Structure of influenza virus ribonucleoprotein particles. II. Purified RNA-free influenza virus ribonucleoprotein forms structures that are indistinguishable from the intact influenza virus ribonucleoprotein particles. J Gen Virol 1995;76:1009-1014.
108. + T cells after gene gun immunization. J Exp Med 1998;188:1075-1082.
109. + T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Db β2m double knockout mice. J Exp Med 1997;185:2043-2051.
110. + Epstein-Barr virus-specific cytotoxic T lymphocytes. J Immunol 1997;158:3619-3625.
111. 111. Whitton JL, Sheng N, Oldstone MB, McKee TA. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol 1993;67:348-352.
112. 112. Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 1995;13:1339-1345.
113. 113. Toes RE, et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci USA 1997;94:14660-14665.
114. 114. Gilbert SC, et al. A protein particle vaccine containing multiple malaria epitopes. Nat Biotechnol 1997;15:1280-1284.
115. 115. Oseroff C, et al. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses. Vaccine 1998;16:823-833.
116. 116. Hanke T, et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 1998;79:83-90.
117. 117. Hanke T, Schneider J, Gilbert SC, Hill AV, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998;16:426-435.